Ampio's Ampion reduces osteoarthritis knee pain
This article was originally published in Scrip
Executive Summary
Ampio Pharmaceuticals reported statistically significant reductions in pain for patients with osteoarthritis of the knee (OAK) in top-line results from the first of two Phase III clinical trials for the biologic Ampion – an intra-articular injection administered at the site of pain and the company's only new molecular entity (NME) in clinical development.